The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight—a systematic literature review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Link
http://link.springer.com/article/10.1007/s00392-017-1102-5/fulltext.html
Reference42 articles.
1. Sorbera LA, Bozzo J, Castaner J (2005) Dabigatran/dabigatran Etexilate. Drugs Future 30:877–885
2. Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880
3. Frost C, Wang J, Nepal S et al (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–487
4. Camm AJ, Bounameaux H (2011) Edoxaban: a new oral direct factor Xa inhibitor. Drugs 71:1503–1526
5. Scaglione F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69–82
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight;Journal of Thrombosis and Haemostasis;2024-07
2. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Low Body Weight Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis;Cardiovascular Drugs and Therapy;2024-01-02
3. Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation;Journal of Thrombosis and Thrombolysis;2023-01-30
4. Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg);The American Journal of Cardiology;2022-12
5. Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase;European Journal of Clinical Pharmacology;2022-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3